GlassScriptPhysician profile
Gloria M Kim
NPI 1366956278
$6,322.63
in general payments reported to CMS, 2019-2025
21 companies · $1,676 in 2025
The $1,676 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $710 · 2023: $1,789 · 2024: $1,720 · 2025: $1,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102 · Education: $82.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,102.45 |
| Education | $82.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,065.87 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $677.90 | 2021-2025 | Trintellix |
| Lundbeck LLC | $602.18 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Corium, LLC | $598.93 | 2022-2025 | Azstarys |
| Alkermes, INC. | $551.61 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $516.85 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $516.18 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $489.42 | 2021-2025 | Rexulti, Nuedexta |
| Collegium Pharmaceutical, INC. | $189.37 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $179.45 | 2022-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $166.83 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Tris Pharma INC | $145.67 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $125.62 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $108.83 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $101.16 | 2023-2025 | Qelbree, Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81.67 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $60.48 | 2024 | Austedo Xr, Uzedy |
| Neos Therapeutics, LP | $59.96 | 2023-2025 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $42.58 | 2022 | |
| Idorsia Pharmaceuticals US INC | $25.98 | 2022-2023 | Quviviq |
| Biogen, INC. | $16.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.